Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs.
作者： Nooshin Dearakhshandeh , Asghar Mogheiseh , Saeed Nazifi , Mohammad Saeed Ahrari Khafi , Mohammad Abbaszadeh Hasiri
DOI: 10.1016/J.THERIOGENOLOGY.2019.10.040
关键词: Tadalafil 、 Urology 、 Hyperplasia 、 Prostatic acid phosphatase 、 Normal group 、 Prostate 、 Medicine 、 Castration 、 Dihydrotestosterone 、 Intact male
摘要: New methods are being developed for the treatment of benign prostatic hyperplasia (BPH) in dogs. The aim present study was to evaluate effects Tadalafil on experimentally induced BPH Twenty-five adult intact male dogs were randomly divided into five groups (n = 5): normal group; with and treated (5 mg/day p.o.); which received castration; BPH. For 4 sequential weeks, hematologic prostate-specific factors (dihydrotestosterone (DHT), serum antigen (PSA), acid phosphatase (PAP), canine specific esterase (CPSE)) measured. Significant differences observed level PSA, CPSE, PAP concentration between vs. BPH-Tadalafil, BPH-castrated, groups. Treating BPH-induced or castration significantly declined levels compared those untreated group. did not affect biomarkers comparison In conclusion, according indices, it could be stated that Tadalafil, castration, used
sci-hub.se 参考文章(51)
M. Gemeiner, J. G. Thalhammer, I. Miller, M. Teinfalt, G. Loupal, Quantitative determination of a canine prostate specific protein and its clinical relevance. Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere. ,vol. 28, pp. 127- 131 ,(2000)
Craig F. Donatucci, Gerald B. Brock, Evan R. Goldfischer, Peter J. Pommerville, Albert Elion-Mboussa, Jay D. Kissel, Lars Viktrup, Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study BJU International. ,vol. 107, pp. 1110- 1116 ,(2011) , 10.1111/J.1464-410X.2010.09687.X
Aleksandra Rył, Iwona Rotter, Tomasz Miazgowski, Marcin Słojewski, Barbara Dołęgowska, Anna Lubkowska, Maria Laszczyńska, Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetology & Metabolic Syndrome. ,vol. 7, pp. 94- 94 ,(2015) , 10.1186/S13098-015-0089-1
Claus G. Roehrborn, Igor Oyarzabal Perez, Erik P.M. Roos, Nicolae Calomfirescu, Betsy Brotherton, Fang Wang, Juan Manuel Palacios, Averyan Vasylyev, Michael J. Manyak, Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJUI. ,vol. 116, pp. 450- 459 ,(2015) , 10.1111/BJU.13033
Masayuki TAKEDA, Osamu NISHIZAWA, Takeshi IMAOKA, Yoji MORISAKI, Lars VIKTRUP, Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension. Luts: Lower Urinary Tract Symptoms. ,vol. 4, pp. 110- 119 ,(2012) , 10.1111/J.1757-5672.2012.00144.X
Thierry Roumeguère, K. Zouaoui Boudjeltia, Claude Hauzeur, Claude Schulman, Michel Vanhaeverbeek, Eric Wespes, Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJUI. ,vol. 104, pp. 511- 517 ,(2009) , 10.1111/J.1464-410X.2009.08418.X
Kaitkanoke Sirinarumitr, Shirley D. Johnston, Margaret V. Root Kustritz, Gary R. Johnston, Dipak K. Sarkar, Mushtaq A. Memon, Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. Javma-journal of The American Veterinary Medical Association. ,vol. 218, pp. 1275- 1280 ,(2001) , 10.2460/JAVMA.2001.218.1275
M. Corazza, G. Guidi, S. Romagnoli, R. Tognetti, A. Buonaccorsi, Serum total prostatic and non‐prostatic acid phosphatase in healthy dogs and in dogs with prostatic diseases Journal of Small Animal Practice. ,vol. 35, pp. 307- 310 ,(1994) , 10.1111/J.1748-5827.1994.TB03292.X
Claus G. Roehrborn, Paul Siami, Jack Barkin, Ronaldo Damião, Kim Major-Walker, Betsy Morrill, Francesco Montorsi, , The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study Journal of Urology. ,vol. 179, pp. 616- 621 ,(2008) , 10.1016/J.JURO.2007.09.084
Chia-Chu Liu, Shu-Pin Huang, Wei-Ming Li, Chii-Jye Wang, Yii-Her Chou, Ching-Chia Li, Chun-Hsiung Huang, Wen-Jeng Wu, Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology. ,vol. 70, pp. 677- 680 ,(2007) , 10.1016/J.UROLOGY.2007.05.025